Four holdings beat earnings across four separate sectors today

AAPL delivered a blowout fiscal Q2 with revenue up 17%, EPS up 22%, and a $100 billion buyback alongside raised guidance of 14-17% growth next quarter. LLY posted 56% revenue growth and early prescription data for its GLP-1 pill Foundayo validated the oral weight-loss pipeline beyond injectables. CBOE beat estimates and raised guidance while announcing a 20% workforce reduction, a combination that points to meaningful margin expansion ahead. CL demonstrated pricing power with 8.4% sales growth despite cost headwinds. Beats this broad, spanning growth, defensive, and financial infrastructure names, are a signal worth noting.

Spirit Airlines rescue collapsed, equity faces total loss

FLYYQ fell 25.71% after a Trump administration-backed $500 million rescue proposal failed to secure sufficient bondholder support, leaving the carrier preparing to shut down entirely. The collapse of a government-backed lifeline removes the last credible recovery scenario for equity holders. With FLYYQ already in bankruptcy proceedings, this development signals liquidation is now the most likely outcome and shareholders should treat remaining equity value as effectively zero.

Three holdings face leadership transitions with uncertain outcomes

OXY announced COO Richard Jackson will replace longtime CEO Vicki Hollub on June 1, ending a defining nine-year era and introducing real questions about future capital allocation strategy. RVMD received FDA early access authorization for its pancreatic cancer pill yet fell 3.23% with no clear negative catalyst, suggesting investor skepticism about commercial potential that the regulatory win alone could not overcome. DJT appointed Kevin McGurn as CEO, a figure whose background is in fusion energy rather than media or finance, raising unresolved questions about strategic direction. Watch all three for clarity on execution before drawing conclusions.